2.50
Hdl Handle:
http://hdl.handle.net/10541/109636
Title:
Adjuvant tamoxifen for male breast cancer (MBC).
Authors:
Ribeiro, G; Swindell, Ric
Abstract:
A study was started in 1976 whereby patients with Stage II and operable Stage III MBC were given adjuvant Tamoxifen for 1 year, increasing to 2 years from 1988. All patients had axillary nodal involvement. Primary treatment consisted of a radical mastectomy or simple mastectomy with radiotherapy. The rarity of the disease precluded a randomised trial. Thirty-nine patients are available for analysis at a median follow-up of 49 months. The actuarial survival of the Tamoxifen treated patients is 61% (range 42-80%) at 5 years compared to 44% (range 35-53%) for historical controls (P = 0.006). Disease-free survival was 56% (37-75%) vs 28% (17-33%) at 5 years (P = 0.005). There were no serious side-effects recorded. The conclusion from this, the first reported series on adjuvant Tamoxifen therapy for MBC, is that significant improvement in disease-free survival can be achieved with minimal upset to the patients. Recruitment to the study continues.
Affiliation:
Department of Clinical Oncology and Medical Statistics, Christie Hospital, Withington, Manchester, UK.
Citation:
Adjuvant tamoxifen for male breast cancer (MBC). 1992, 65 (2):252-4 Br J Cancer
Journal:
British Journal of Cancer
Issue Date:
Feb-1992
URI:
http://hdl.handle.net/10541/109636
PubMed ID:
1739625
Type:
Article
Language:
en
ISSN:
0007-0920
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorRibeiro, Gen
dc.contributor.authorSwindell, Ricen
dc.date.accessioned2010-08-16T12:07:36Z-
dc.date.available2010-08-16T12:07:36Z-
dc.date.issued1992-02-
dc.identifier.citationAdjuvant tamoxifen for male breast cancer (MBC). 1992, 65 (2):252-4 Br J Canceren
dc.identifier.issn0007-0920-
dc.identifier.pmid1739625-
dc.identifier.urihttp://hdl.handle.net/10541/109636-
dc.description.abstractA study was started in 1976 whereby patients with Stage II and operable Stage III MBC were given adjuvant Tamoxifen for 1 year, increasing to 2 years from 1988. All patients had axillary nodal involvement. Primary treatment consisted of a radical mastectomy or simple mastectomy with radiotherapy. The rarity of the disease precluded a randomised trial. Thirty-nine patients are available for analysis at a median follow-up of 49 months. The actuarial survival of the Tamoxifen treated patients is 61% (range 42-80%) at 5 years compared to 44% (range 35-53%) for historical controls (P = 0.006). Disease-free survival was 56% (37-75%) vs 28% (17-33%) at 5 years (P = 0.005). There were no serious side-effects recorded. The conclusion from this, the first reported series on adjuvant Tamoxifen therapy for MBC, is that significant improvement in disease-free survival can be achieved with minimal upset to the patients. Recruitment to the study continues.en
dc.language.isoenen
dc.subjectBreast Canceren
dc.subject.meshActuarial Analysis-
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshBreast Neoplasms-
dc.subject.meshHumans-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshSurvival Analysis-
dc.subject.meshTamoxifen-
dc.titleAdjuvant tamoxifen for male breast cancer (MBC).en
dc.typeArticleen
dc.contributor.departmentDepartment of Clinical Oncology and Medical Statistics, Christie Hospital, Withington, Manchester, UK.en
dc.identifier.journalBritish Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.